Green Hydrogen Systems’ extraordinary general meeting on 14 November 2024
Green Hydrogen Systems A/S
Decisions at extraordinary general meeting
Green Hydrogen Systems’ extraordinary general meeting on 14 November 2024
Today on 14 November 2024, an extraordinary general meeting of Green Hydrogen A/S was held at Plesner Law Firm P/S on Amerika Plads 37, DK-2100 Copenhagen, Denmark
On the Extraordinary General Meeting of the shareholders resolved:
1) to adopt a share capital reduction by way of transfer to a special reserve, including a proposal to adopt a reduction in the nominal value of each share;
2) to issue an an authorisation to the Board of Directors to issue shares without pre-emption rights;
3) to issue authorisations to the Board of Directors to issue shares with pre-emption rights and warrants without pre-emption rights; and
4) to issue an authorisation to the Board of Directors to issue convertible bonds without pre-emption rights
Copenhagen, Denmark, 14 November 2024
Board of directors of Green Hydrogen Systems A/S
*****
For more info please contact:
Lene Rode, Head of Communications & External Relations, +45 4085 2619, [email protected]
Green Hydrogen Systems in brief
Green Hydrogen Systems is a clean technology company and a leading provider of standardised and modular electrolysers for the production of green hydrogen solely based on renewable energy. With its wide range of possible applications, green hydrogen plays a key role in the ongoing fundamental shift in our energy systems towards a net-zero emission society in 2050. As a result, the demand for green hydrogen is surging, requiring a significant scale-up of electrolysis capacity. Founded in 2007 and building on more than 15 years of technology development, Green Hydrogen Systems today have a commercially proven and cost-competitive electrolysis technology endorsed by leading green energy companies.
Source: Green Hydrogen Systems
Ticker: GREENH
Attachment
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
- Admirals Group AS Announces a Sale of its Australian Subsidiary
- Building Homes for Heroes Gifts 400th Home, Marking Historic Achievement in Veteran and First Responder Support
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!